BrainCells, Taisho Pharmaceutical, sign licensing agreement for novel CNS program
BrainCells Inc. (BCI) and Taisho Pharmaceutical Co., Ltd. (Taisho) today announced that BCI has in-licensed a novel development program from Taisho that BCI will develop for central nervous system (CNS) indications, including mood disorders. Taisho retains rights to the program in Japan and China, while BCI will have rights for the remainder of the world. Financial terms were not disclosed.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.